AI Generated Image
Thyroid medicine recalled. See affected product
USA Today • • business
Key Points:
- Vitruvias Therapeutics Inc. has recalled a specific lot of its 30 mg thyroid tablets due to concerns the product may be superpotent, potentially causing adverse health effects.
- The recall affects approximately 3,600 units distributed nationwide between January and September 2025, with an expiration date of September 30, 2026; about 1,900 units have already been sold.
- The affected tablets can be identified by National Drug Code 69680-166-00 or lot number 504950 and are labeled "Thyroid Tablets, USP."
- Consuming superpotent thyroid tablets may lead to symptoms of an overactive thyroid, such as weight loss, heat intolerance, fatigue, and hypertension; however, no adverse events have been reported so far.
- Patients taking the recalled medication are advised not to stop without consulting their healthcare provider and can contact Vitruvias Therapeutics for further information.
